Aditxt Inc. will host a scientific update on May 2, 2025, featuring prominent researchers discussing recent developments in immune modulation therapy. Dr. Charles Howe from the Mayo Clinic will present key findings from a preclinical study of ADI-100™, the lead therapeutic candidate from Aditxt's subsidiary, Adimune Inc.
The update will include presentations by Dr. Shahrokh Shabahang, Aditxt's Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune. These experts will provide insights into the latest advancements in immune health research and potential therapeutic interventions.
This event represents an important milestone for Aditxt, which operates as an innovation platform dedicated to accelerating promising health innovations. The company's strategic approach involves collaborating with research institutions and industry partners to address significant societal health challenges.
The preclinical study update is particularly significant as it offers a potential glimpse into emerging approaches in immune modulation. By presenting scientific findings from a prestigious institution like Mayo Clinic, Aditxt aims to demonstrate the potential of its therapeutic research and development efforts.
As part of its broader strategy, Aditxt is developing programs focused on immune health, precision health, and plans to introduce additional initiatives in public health and women's health. The company's collaborative model seeks to democratize innovation and ensure comprehensive stakeholder engagement in medical research.
